New chemo cocktail aims to boost remission in elderly AML patients
NCT ID NCT06744556
First seen May 14, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tests whether a new combination of chemotherapy drugs (HAV) works better than another combo (DAV/IAV) for adults aged 60-75 with acute myeloid leukemia (AML). About 41 participants will receive one of the two treatments to see which leads to longer remission and survival. The goal is to improve outcomes for older patients who often have limited treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.